• Deuterated CYP51 Inhibitors: C52 and Oteseconazole

  2026-09-09

  The 2025 Journal of Medicinal Chemistry study designed deuterated diphenyl azole alcohol derivatives by combining structural features of Oteseconazole and A33. Compound C52 emerged as a broad-spectrum, antibiofilm CYP51-targeting candidate with activity against a resistant fungal strain, favorable oral pharmacokinetics, and 63.4% oral bioavailability in the reported preclinical evaluation.

• TMRE, Mitochondrial Potential, and NECSO

  2026-09-08

  Sodium overload can trigger mitochondrial energy failure before a cell reaches irreversible necrotic lysis. This thought-leadership article connects the NECSO mechanism described by Qiao and colleagues with practical TMRE-based measurements of mitochondrial membrane potential, showing how translational researchers can distinguish mitochondrial depolarization from downstream loss of viability. It also outlines experimental controls, assay limitations, and a strategic path toward higher-confidence mitochondrial function analysis.

• Parthenolide, ROS, and Lymphoid Cancer Apoptosis

  2026-09-08

  The reference study shows that parthenolide suppresses metabolic activity and promotes apoptosis across diverse B- and T-lineage lymphoid malignancy models through oxidative stress, glutathione depletion, and mitochondrial dysfunction. Its integrated use of resazurin-based metabolic profiling, flow cytometry, and qPCR illustrates how a cell viability assay can identify treatment responses while mechanistic assays establish whether reduced signal reflects apoptosis and redox injury.

• Cy3 RNA Probes for Mechanistic Sepsis Research

  2026-09-07

  Translational sepsis research depends on connecting biomarker abundance with transcript localization, molecular integrity, and pathway activity. This thought-leadership guide explains how the HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit can support mechanistic RNA detection, using the MALAT1–miR-125b–STAT3–PCT axis as a model for designing more rigorous in situ hybridization and Northern blot workflows.

• 1-phenyl-1H-pyrazolo[3,4-d]pyrimidin-4-amine

  2026-09-07

  PP 3 is a DMSO-soluble kinase inhibitor control compound designed to separate Src-associated effects from vehicle, assay, and pathway-specific responses. Its paired use with PP 2 is especially useful when interpreting vascular signaling experiments involving NADPH oxidase-derived ROS and L-type calcium channels.

• o-Agatoxin IVA in Cortical Excitotoxicity

  2026-09-05

  Lustig, Ahem, and Greenberg tested whether blocking P- and Q-type voltage-gated calcium channels with o-Agatoxin IVA could reduce excitotoxic injury in cultured cortical neurons. Their results showed that agatoxin, nimodipine, and ω-conotoxin GVIA did not prevent injury induced by veratridine, ouabain, or NMDA, cautioning that inhibition of glutamate release does not necessarily produce neuroprotection.

• HyperScribe T7 Cy3 RNA Labeling Kit Guide

  2026-09-04

  The HyperScribe T7 High Yield Cy3 RNA Labeling Kit is a Cy3 RNA labeling kit for generating fluorescent RNA probes by T7 RNA polymerase transcription. Its supplied Cy3-UTP, nucleotide mix, control template, and RNase-free water support in situ hybridization and Northern blot fluorescent probe workflows, while the Cy3-UTP:UTP ratio can be adjusted for the required balance between probe yield and signal.

• Lipidated Nanophotosensitizer Disables Tumor EVs

  2026-09-04

  A 2025 Nature Cancer study developed a palmitic acid-displayed nanophotosensitizer that traces tumor extracellular vesicles (TEVs) and disables them under near-infrared irradiation. By generating reactive oxygen species in both primary tumor cells and TEVs, the strategy suppressed tumor growth while interrupting prometastatic communication in multiple mouse models.

• PD98059 Workflows for MEK–ERK Research

  2026-09-03

  PD98059 provides a reversible pharmacological switch for testing whether MEK–ERK signaling drives proliferation, apoptosis, oxidative injury, or tissue damage. This practical guide connects concentration finding, pathway validation, and troubleshooting across leukemia, liver-injury, and ischemia research models.

• Stable-Isotope UHPLC–MS/MS for Methylated Purines

  2026-09-03

  Zhang, Zhang, and Wang developed a stable isotope-diluted UHPLC–ESI-MS/MS method for accurate measurement of 12 purine ribonucleosides, including 10 methylated species, in complex cellular extracts. Ammonium bicarbonate-enhanced ionization, chromatographic isomer resolution, methanol extraction, and solid-phase cleanup together improved sensitivity and enabled quantification of low-abundance modified nucleosides in 293T cells.

• BATF2–ATF3 Drives Mitochondrial Dysfunction in IVDD

  2026-09-02

  The reference study identifies a BATF2–ATF3 regulatory axis that links mitochondrial redox disruption with nucleus pulposus cell apoptosis and extracellular-matrix degradation in intervertebral disc degeneration. Its combination of human tissue analysis, cellular perturbation, and rescue experiments provides a mechanistic framework for evaluating BATF2–ATF3 signaling as a potential IVDD target.

• TMRE mitochondrial membrane potential assay kit guide

  2026-09-02

  Use TMRE fluorescence to connect mitochondrial depolarization with apoptosis, sodium-driven energy failure, and broader mitochondrial function analysis. This practical guide covers assay setup, quantitative normalization, high-throughput workflows, and troubleshooting for cell, tissue, and purified mitochondria samples.

• Doxorubicin Hydrochloride: Assay Design

  2026-09-01

  Doxorubicin hydrochloride is more than a cytotoxicity benchmark: it can anchor a paired assay strategy connecting tumor-cell damage with cardiac stress. This guide integrates Adriamycin HCl handling, orthogonal readouts, and cardiotoxicity-model interpretation.

• ABT-263: State-Dependent Apoptosis in Cancer Models

  2026-09-01

  ABT-263 (Navitoclax) is a powerful tool for testing how Bcl-2 family dependence changes after chemotherapy. This article translates senescence-focused findings into practical decisions for apoptosis assays, model selection, and mechanistic validation.

• Topotecan HCl: From DNA Damage to Translation

  2026-08-31

  Topotecan HCl is more than a cytotoxic benchmark: it is a mechanistically defined topoisomerase 1 inhibitor for studying replication-associated DNA damage, cell-state adaptation, and schedule-dependent antitumor response. This article translates its biology into practical assay design and a strategy for stronger lung and prostate cancer research.

8507 records 1/568 page Next 12345 下5页 Last page